Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. [PDF]
, 2015 BackgroundPatients with BRAF mutation-positive advanced melanoma respond well to matched therapy with BRAF or MEK inhibitors, but often quickly develop resistance.MethodsTumor tissue from ten patients with advanced BRAF mutation-positive melanoma who ...
Cronin, Maureen T +9 more
core +3 more sources
Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model. [PDF]
, 2017 An excessive requirement for methionine termed methionine dependence, appears to be a general metabolic defect in cancer. We have previously shown that cancer-cell growth can be selectively arrested by methionine deprivation such as with recombinant ...
Chmielowski, Bartosz +15 more
core +2 more sources
Frontiers in Pigment Cell and Melanoma Research
, 2018 We identify emerging frontiers in clinical and basic research of melanocyte biology and its associated biomedical disciplines. We describe challenges and opportunities in clinical and basic research of normal and diseased melanocytes that impact current ...
Birlea, Stanca +26 more
core +1 more source
BRAF inhibitor and hairy cell leukemia-related transient acantholytic dermatosis [PDF]
, 2020 Grover disease (GD) is an acquired, nonfamilial, nonimmune mediated, transient or persistent acantholytic dermatosis. Herein, we present a 72-year-old man who had clinical and histopathologic findings of GD following two weeks of treatment with ...
Durkin, John R +3 more
core
Recent advances in managing differentiated thyroid cancer [PDF]
, 2018 The main clinical challenge in the management of thyroid cancer is to avoid over-treatment and over-diagnosis in patients with lower-risk disease while promptly identifying those patients with more advanced or high-risk disease requiring aggressive ...
Durante, Cosimo +3 more
core +2 more sources
Molecular Cancer, 2017 Background Most melanoma patients with BRAFV600E positive tumors respond well to a combination of BRAF kinase and MEK inhibitors. However, some patients are intrinsically resistant while the majority of patients eventually develop drug resistance to the ...
Giulia Cesi +4 more
doaj +1 more source
SREBP1-dependent de novo fatty acid synthesis gene expression is elevated in malignant melanoma and represents a cellular survival trait. [PDF]
, 2019 de novo fatty acid biosynthesis (DNFA) is a hallmark adaptation of many cancers that supports survival, proliferation, and metastasis. Here we elucidate previously unexplored aspects of transcription regulation and clinical relevance of DNFA in cancers ...
Näär, Anders M, Wu, Su
core
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. [PDF]
, 2019 BackgroundThis pooled analysis investigated the prognostic value of depth of response in two cohorts of patients with BRAFV600-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib.MethodsThe data were pooled from BRIM-2 ...
Ascierto, Paolo A +12 more
core +2 more sources
Chinese Journal of Lung Cancer, 2019 BRAF gene mutation is found in about 2%-4% of the patients with non-small cell lung cancer (NSCLC). This type of NSCLC is characterized by high malignancy, low efficacy of chemotherapy and poor prognosis.
Xia LIU, Diansheng ZHONG
doaj +1 more source
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Cell Death and DiseaseMetastatic BRAF V600E colorectal cancer (CRC) carries an extremely poor prognosis and is in urgent need of effective new treatments. While the BRAFV600E inhibitor encorafenib in combination with the EGFR inhibitor cetuximab (Enc+Cet) was recently ...
Laura J. Jenkins +19 more
doaj +1 more source